Therapy decision making based on the molecular properties of CTCs

The Fraunhofer ITEM Personalized Tumor in Regensburg develops custom-tailored workflows for the enrichment, detection, and molecular analysis of tumor cells in blood and other organs and their implementation in clinical diagnostic procedures. In an international study, we combined the CellSearch® system, the gold standard for CTC enrichment and detection, with the DEPArrayTM system for automated single-cell isolation and Ampli1TM, an in-house developed method for amplification of the whole genome (DNA) of a single cell. Application of this approach in controlled clinical therapy studies – for example, in the ongoing DETECT studies – now aims to evaluate whether the molecular profile of CTCs can predict success of targeted therapies in individual patients and to help uncover emerging therapy resistance at an early time point.

 

Publications

  1. Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, Andergassen U, Meier-Stiegen F, Czyz ZT, Alberter B, Treitschke S, Schamberger T, Sergio M, Bregola G, Doffini A, Gianni S, Calanca A, Signorini G, Bolognesi C, Hartmann A, Fasching PA, Sandri MT, Rack B, Fehm R, Giorgini G, Manaresi N, Klein CA. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med 2014; 6 (11): 1371-86.
  2. Neves RP, Raba K, Schmidt O, Honisch E, Meier-Stiegen F, Behrens B, Möhlendick B, Fehm T, Neubauer H, Klein CA, Polzer B, Sproll C, Fischer JC, Niederacher D, Stoecklein NH. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Clin Chem 2014; 60 (10): 1290-7.
  3. Alberter B, Klein CA, Polzer B. Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. Expert Rev Mol Diagn. 2016 Jan; 16 (1): 25-38. doi: 10.1586/14737159.2016.1121099. Epub 2015 Dec 5.